Sana Biotechnology (SANA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Samantha Semenkow from Citi remains neutral on the stock and has a $8.00 price target.
Samantha Semenkow has given her Buy rating due to a combination of factors, chief among them the promising initial data from Sana Biotechnology’s ARDENT clinical trial. The preliminary results on the first patient treated with SC291, an allogeneic HIP-modified CD19 CAR-T therapy, showed a partial response at day 28. This is a notable achievement considering the patient had chronic lymphocytic leukemia with poor prognostic markers and had not responded to three prior lines of therapy. The potential for SC291 to evade the immune response was also demonstrated in ex vivo immunogenicity studies, suggesting the therapy’s ability to resist clearance by the patient’s own immune cells.
Semenkow’s optimism is further bolstered by the company’s plan to release a more comprehensive dataset in early 2024, which is expected to include additional patients and extended follow-up. This future data could provide a clearer picture of SC291’s efficacy and further substantiate the early efficacy signals. Although the abstract was not accepted for presentation at the ASH conference due to the early stage of data and the high volume of submissions for CD19-targeted CAR-T programs, the financial analyst remains confident in the stock’s potential. This confidence is reflected in the Buy rating, underscored by the anticipation of a more detailed update, which could validate the platform’s hypoimmune capabilities and support Sana’s innovative approach to treatment.
Semenkow covers the Healthcare sector, focusing on stocks such as Immunovant, Beam Therapeutics, and Sana Biotechnology. According to TipRanks, Semenkow has an average return of 0.8% and a 53.33% success rate on recommended stocks.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Sana Biotechnology (SANA) Company Description:
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
Read More on SANA:
- Sana Biotechnology publishes data showing SC291 evaded immune detection
- Sana Biotechnology to Present at November and December 2023 Investor Conferences
- Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
- Sana, Uppsala announce authorization of first-in-human study of UP421
- Sana: FDA clears IND to study SC291 for B-cell mediated autoimmune diseases
